Recombinant CPA1 anticorps (full length)

N° du produit ABIN7877799

L’anticorps anti-CPA1 Monoclonal Lapin est utilisé pour la détection de CPA1 dans des échantillons de Humain. Il a été validé pour IHC (p).

Aperçu rapide pour Recombinant CPA1 anticorps (full length) (ABIN7877799)

Antigène: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp CPA1 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: CPA1-8259R

Détail du produit anti-CPA1 anticorps

Épitope: full length

Fonction: CPA1 Antibody / Carboxypeptidase A1

Purification: Protein A/G affinity

Immunogène: Recombinant full-length human CPA1 protein was used as the immunogen for the CPA1 antibody.

Isotype: IgG, kappa

Information d'application

Indications d'application: Optimal dilution of the CPA1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Aliquot the CPA1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Détails sur CPA1

Antigène: CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))

Autre désignation: CPA1

Sujet: Human pancreatic procarboxypeptidase A exists as three different active forms, two of which are designated carboxypeptidase A1 (CPA1) and carboxypeptidase A2 (CPA2). CPA1, also known as CPA, is a 419 amino acid secreted monomeric protein that is highly expressed in pancreatic tissue. Functioning as a pancreatic exopeptidase, CPA1 uses zinc as a cofactor to catalyze the release of C-terminal amino acids from a variety of proteins, thereby playing a key role in protein digestion and degradation. Via its catalytic activity, CPA1 is also thought to be involved in zymogen (proenzyme) inhibition, probably functioning to block enzyme activation pathways. Abnormal levels of CPA1 are associated with pancreatic cancer, suggesting a possible role in either tumor progression or tumor suppression events.

UniProt: P15085